Source comparison
Tolerance to TB-500 Cycling: Protocol Comparison
Protocol designs vary significantly across tissue types and injury models, affecting how tolerance manifests—or doesn't. Standard Tissue Repair 4–6 weeks 2–4 weeks 2–3 cycles 85–95% of initial response maintained through cycle 3 Best for acute injury models wh
This comparison does not assign a generated winner or score.
- Protocol designs vary significantly across tissue types and injury models, affecting how tolerance manifests—or doesn't.
- Standard Tissue Repair
- 4–6 weeks
- 2–4 weeks
- 2–3 cycles
- 85–95% of initial response maintained through cycle 3
- Best for acute injury models where repair completion is the endpoint—tolerance minimal because substrate becomes limiting factor
- Extended Continuous Dosing
- 8–12 weeks
- None
- Single continuous phase
- Plateau observed around week 6–8 as repair approaches completion
- Not true tolerance—benefits plateau when tissue integrity normalizes; extending beyond 8 weeks adds marginal value in most models
- Loading + Maintenance
- 7-day loading (daily) followed by 4–6 weeks (2–3x weekly)
- 3–4 weeks
- 2–4 cycles
- Consistent response across all cycles with no measurable decline
- Frontloads actin-binding activity without over-saturating pathways; optimal for chronic injury models requiring sustained remodeling
- Rotating Multi-Peptide Stack
- 4 weeks TB-500, 4 weeks BPC-157 alternating
- Minimal (3–7 days between switches)
- 3–6 alternating cycles
- Independent efficacy maintained for each peptide across all cycles
- Avoids pathway overlap; particularly effective when combining regenerative mechanisms (TB-500 + BPC-157 + growth factors)
- Short-Cycle Pulsing
- 2–3 weeks on
- 2–3 weeks off
- 4–6 cycles
- Equivalent cumulative benefit to longer cycles with identical tolerance profile
- Matches dosing to acute inflammatory phases; useful when injury is episodic or when monitoring biomarkers between cycles